| ABSTRACT Objective:To evaluate systematically the clinical effectiveness and safety of Purearin injection in treatment of Cerebral Infarction(CI). Methods:Randomized controlled trials(RCTs) regarding CI treated by Purearin injection and conventional therapy in the China National Knowledge Infrastructure Database, China Scienceand Technology Journal Database, Wanfang Database, Chinese Biomedical Literature Database, PubMed and the Cochrane Library up to 22nd October, 2016. Two reviewers independently retrieved RCTs and extracted information. The Cochrane risk of bias method was used to assess the quality of included studies, and a Meta analysis was conducted with ReMan 5.3 software. Results:A total of 18 RCTs involving 1 624 participants were included, 824 cases in Purearin injection group and 800 cases in the routine western medicine group. In Meta analysis, the results of Purearin injection group was significantly superior to the routine western medicine group in the total effective rates(RR=1.21, 95%CI: 1.15 1.26, P<0.000 01). And Purearin injection could have effects on neurologic impairment(MD=-5.03, 95%CI:-6.88 -3.17, P<0.000 01), hemorheological parameters and other outcomes. Two articles cleared that there was no ADRs in the studies, 5 studies reported 26 cases of ADRs. Conclusion: Purearin injection combined with conventional therapy has good therapeutic effect on CI, while its safety still needs to be further investigated. |
